Related Experiment Videos
[Renal osteodystrophy: aluminium and secondary hyperparathyroidism]
1INSERM U 18, Centre Viggo-Petersen, Paris.
La Revue Du Praticien
|March 1, 1990
Summary
Aluminium overload causes osteodystrophy by directly harming bone cells and lowering parathormone. Preventing secondary hyperparathyroidism is key for managing this condition in dialysis patients.
Area of Science:
- Bone biology
- Endocrinology
- Nephrology
Background:
- Aluminium-related osteodystrophy presents as osteomalacia or aplastic bone with reduced bone cell activity but normal mineralization.
- Aluminium toxicity directly impacts osteoblasts, leading to their depression during significant overload.
- Aluminium accumulation in parathyroid glands often results in low parathormone levels, complicating bone disease understanding.
Purpose of the Study:
- To elucidate the complex interplay between aluminium deposition, parathormone levels, and the pathogenesis of aplastic bone disease.
- To clarify the role of parathormone in modulating the effects of aluminium on bone tissue.
- To investigate the clinical course and therapeutic strategies for aluminium-related osteodystrophy, particularly in haemodialysis patients.
Main Methods:
- Observational analysis of bone tissue and parathyroid gland pathology in patients with aluminium overload.
- Correlation of aluminium levels in bone and serum with parathormone concentrations.
- Clinical assessment of patients with aplastic bone, including those without aluminium deposits.
Main Results:
- Aluminium directly impairs osteoblast activity, contributing to osteodystrophy.
- Low parathormone levels, often due to aluminium accumulation, are associated with aluminium-related osteopathy.
- Parathormone levels influence bone aluminium burden; hyperparathyroidism offers protection, while parathyroidectomy increases bone aluminium deposition.
- Some patients with aplastic bone show no aluminium deposits but have normal or low parathormone levels, with many remaining asymptomatic.
Conclusions:
- Aluminium toxicity and altered parathormone dynamics are critical factors in osteodystrophy development.
- Preventing secondary hyperparathyroidism and avoiding aluminium hydroxide are crucial therapeutic goals for haemodialysis patients.
- Further research is needed to determine the long-term clinical course of aplastic osteopathy in patients without aluminium deposits.